Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about using a dermastamp for hair loss treatment and concerns about a potentially scam product, pp405. It suggests sticking with known treatments like finasteride and minoxidil.

Hair loss treatments, including PP405, minoxidil, finasteride, and RU58841, with hopes for future solutions. Participants discuss the emotional impact of hair loss and consider alternatives like hair transplants or acceptance.

The user was rejected from participating in a clinical trial for an extended-release oral Minoxidil due to having rheumatoid arthritis, despite initially being accepted. They had stopped using Dutasteride and Minoxidil to qualify but continued using other treatments like RU58841 and red light therapy.

The effects of Finasteride on hair loss and its side-effects, such as aching balls. The user has been taking it for two years with no changes to the symptom.

Veradermics' phase 2 trial of slow-release oral minoxidil shows promising hair regrowth with minimized side effects, gaining significant attention and funding. PP405 is also noted for its potential as a side-effect-free alternative.

Topical melatonin may help with inflammation-induced hair loss. The user plans to try it and share results.

The user has been microneedling for 4 weeks and using treatments like minoxidil and eclipta alba oil, seeing positive but slow results. They are considering peppermint oil as a potentially more effective alternative to minoxidil.

PP405 is a promising hair loss treatment that may outperform minoxidil and finasteride by reviving dormant follicles and promoting significant regrowth. Results from ongoing trials are awaited, with a potential market release between 2028-2030.

The user reported positive hair regrowth after 11 months on finasteride and 4 months of microneedling. Opinions in the conversation vary, with some endorsing microneedling as effective and others emphasizing finasteride as essential, while acknowledging that treatments may not work for everyone.

The conversation discusses treatments for scalp inflammation, suggesting options like scalp massage, changing shampoos, using aloe vera, Tgel, nizoral shampoo, topical cetirizine, and consulting a dermatologist. Finasteride was mentioned as helpful for reducing inflammation, but with side effects.

Melatonin's effect on aromatase expression is unclear, with studies showing both increases and decreases. Hormonal impacts are complex and inconsistent, similar to changing health advice on other substances.

Hope Medicine received a $28M investment for HMI-115, a monoclonal antibody in phase II trials for treating androgenetic alopecia. Some users are skeptical about its effectiveness, while others find the investment and trial results encouraging.

The conversation discusses the potential benefits and risks of participating in the PP405 hair loss trials, emphasizing that those using Minoxidil or finasteride are less likely to be accepted. Participants are interested in the trial as it offers hope for effective treatment without the side effects associated with current medications.

Pyrilitamide (KX-826) did not show significant improvement in hair count compared to placebo after 6 months. It's unclear if it can maintain hair at baseline.

Finasteride and dutasteride may not significantly impact meibomian gland function since these glands do not rely on DHT. Some users report dry eyes and other side effects from finasteride, but these may be influenced by other factors or medications.

A 19-year-old male experienced significant hair loss, initially thought to be male pattern baldness (MPB), and used minoxidil and briefly finasteride. After realizing the issue was telogen effluvium (TE), he improved his diet and supplemented with vitamins, which led to substantial hair regrowth.

PP405 updates are seen as vague and lacking substance, causing frustration among users. Some users report positive effects from using minoxidil and dutasteride, while others remain skeptical about new treatments.

PP405 is considered as a potential hair regrowth treatment, but users are skeptical due to past product failures. They compare it to Minoxidil and Finasteride, questioning its effectiveness and the intentions of pharmaceutical companies.

A 21-year-old is experiencing aggressive hair loss and dandruff, possibly due to seborrheic dermatitis, and is using pumpkin seed oil, scalp massages, and anti-dandruff shampoo as treatments. They are hesitant to use prescribed Finasteride and Minoxidil and have noticed some improvement after stopping Serenoa capsules.

PP405 is considered a promising hair loss treatment, potentially replacing minoxidil but not finasteride. Users are hopeful for future treatments like GT20029 and VDPHL01, while remaining cautious about effectiveness and side effects.

A user is concerned that finasteride isn't working for their hair loss, questioning if it's due to male pattern baldness or low iron levels. They are advised to take finasteride daily and get blood work done.

Kintor's 1% Pyrilutamide will be released in October/November. The user cannot tolerate finasteride.

Latanoprost at 0.1% concentration is used to increase hair counts, often mixed with Minoxidil and Finasteride. Users report noticeable results in about 3 months.

The user is experiencing aggressive diffuse thinning despite using 1mg oral finasteride daily, topical minoxidil twice, microneedling, and Nizoral for seborrheic dermatitis. They are considering switching to dutasteride or RU58841 but are advised to seek a second opinion to determine the cause of hair loss.

Adipose-derived stem cell secretome showed significant improvement in hair density and growth, especially when combined with minoxidil, suggesting a synergistic effect. The study had limitations, including a small sample size and potential bias.

PP405 is a new hair loss treatment facing mixed reactions due to initial hype and insufficient data. Some are hopeful, but many doubt its effectiveness compared to minoxidil and finasteride.

The user asks if finasteride can be used with the topical steroid betamethasone dipropionate to reduce hair loss and scalp inflammation. The discussion revolves around combining these treatments for better results.

Analyzing data on pyrilutamide, a potential hair loss treatment, as well as the effectiveness of other treatments such as Minoxidil, Finasteride, and RU58841.

User shares 4-month progress using daily minoxidil, topical finasteride, and microneedling. Results spark debate on effectiveness and authenticity.

Microneedling with RU58841 may not be necessary since RU works topically by occupying receptors before DHT binds. RU58841 is a topical anti-androgen.